Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 21fludarabine phosphate 18Whole-Body Irradiation 17Melphalan 15fludarabine 14Tacrolimus 14Busulfan 12Mycophenolic Acid 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 8Methotrexate 5Cyclosporine 5Antilymphocyte Serum 5thymoglobulin 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3sargramostim 2Transplantation 2Sirolimus 2Rituximab 2Methylprednisolone 2Mesna 2Influenza Vaccines 2Immunoenzyme Techniques 2Hematopoietic Stem Cell Transplantation 2Flow Cytometry 2Filgrastim 2Etoposide 2Cord Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia, Aplastic × visilizumab × Clear all
NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
8 enrolled 11 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡